Shorter Initial Benzo Courses Linked to Discontinuation
Overview
A study published in PLOS Medicine analyzed linked administrative health care data from 1.8 million adults in Ontario, Canada, who received a new oral benzodiazepine prescription from 2013 to 2020, with follow-up through 2021. The study found that patients prescribed longer initial benzodiazepine courses were less likely to discontinue treatment.
Background
Benzodiazepines are commonly prescribed for various mental health conditions, yet their prolonged use raises concerns regarding safety and dependency.
Data Highlights
| Prescription Duration | Likelihood of Discontinuation |
|---|---|
| 7 days or fewer | Reference |
| 8 to 14 days | 50% lower likelihood |
| 15 to 30 days | 75% lower likelihood |
| More than 30 days | 86% lower likelihood |
Key Findings
- Longer initial benzodiazepine prescriptions were associated with lower discontinuation rates.
- Patients prescribed 8 to 14 days had about half the likelihood of discontinuation compared to those prescribed 7 days or fewer.
- Prescriptions of 15 to 30 days were associated with about one-quarter the likelihood of discontinuation.
- Patients initially dispensed 2 or more benzodiazepines were less likely to discontinue treatment.
- The median time to discontinuation was 19 days overall, with variations by sex.
Clinical Implications
The findings indicate that initial prescription duration may influence patient adherence to benzodiazepine treatment.
Conclusion
This study reports a relationship between initial benzodiazepine prescription duration and treatment discontinuation.
Related Resources & Content
- PLOS Medicine, 2026 -- Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study
- Frontiers in Psychiatry — Toward clarifying ASAM’s inpatient and residential benzodiazepine tapering recommendations
- Frontiers in Psychiatry — Psychotherapy initiation is associated with discontinuation of psychotropic medications without dose escalation: a ten-year real-world cohort study (2014-2024)
- Archives of Toxicology — Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam
- Intensive Care Medicine — Management of Elevated Benzodiazepine Metabolites with Rifampicin in a Comatose Patient Following Overdose and Trauma
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits - PMC
- Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
